Biotech stock Olema Pharmaceuticals (OLMA) catapulted to a four-year high Tuesday, up more than 100%, after Roche (RHHBY) unveiled positive results for its rival breast cancer treatment. The Swiss pharma giant tested its drug, giredestrant, in patients with early-stage breast cancer. Roche’s pill is a selective estrogen receptor degrader, or SERD. It breaks down the estrogen cancer cells need to…
